^
    Back
    Association details:
    Biomarker:NECTIN4 expression
    Cancer:Solid Tumor
    Drug:SBT6290 (Nectin-4-targeted antibody-drug conjugate, TLR8 agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

    Excerpt:
    ...- Locally advanced or metastatic solid tumors associated associated with Nectin-4 expression (locally advanced or metastatic urothelial carcinoma, TNBC, NSCLC, SCCHN, and HR+/HER2- negative breast cancer)...
    Trial ID:
    NCT05234606
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Res
    Title:

    Abstract 1858: SBT6290, a systemically administered Nectin4-directed TLR8 ImmunoTAC™ product candidate, is designed for tumor-localized activation of myeloid cells

    Published date:
    07/01/2021
    Excerpt:
    Systemic administration of a SBT6290 surrogate in mice bearing Nectin4-expressing tumors results in intra-tumoral myeloid and T cell activation and increased overall survival. The preclinical data described here demonstrate the potential for SBT6290 to drive anti-tumor responses and support continued preclinical development of SBT6290 for Nectin4-expressing tumors.
    DOI:
    https://doi.org/10.1158/1538-7445.AM2021-1858